

JAN 29 1999

16983328

## SUMMARY OF SAFETY AND EFFECTIVENESS

### Alkaline Phosphatase (AMP) Method for the ADVIA IMS Systems

Listed below is a comparison of the performance of the Bayer ADVIA Alkaline Phosphatase (AMP) method and a similar device that was granted clearance of substantial equivalence (Bayer Chem 1 ALP(AMP) method). The information was extracted from the Bayer ADVIA ALP(AMP) method and Bayer Chem 1 method sheet.

#### INTENDED USE

The Bayer ADVIA IMS alkaline phosphatase (ALP) assay is an *in-vitro* diagnostic device intended to measure ALP in human serum or plasma. Such measurements are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. This diagnostic method is not intended for use on any other diagnostic system.

ALP(AMP) METHOD:	ADVIA IMS		CHEM 1	
Part Number:	Reagents B41-3718-23		T01-1459-53	
Analytical Range:	0 to 2800 U/L		0 to 2250 U/L	
Precision (Total):	mean (U/L)	% CV	mean (U/L)	% CV
	74	3.6	65	3.8
	160	2.9	263	3.3
	420	2.1	547	3.2

Regression Equation:  $y = 0.96x + 2.0$   
(serum)

where: y = ADVIA IMS  
x = Chem 1  
n = 74  
r = 0.999  
Sy.x = 11.2  
range = 36 to 1599 U/L


Regression Equation:  $y = 1.06x - 0.9$   
(plasma qualification)

where: y = plasma  
x = serum  
n = 59  
r = 0.999  
Sy.x = 0.93  
range = 33 to 111 U/L

000167

*Interference*

	Interfering Substance Concentration	ALP(AMP)	Effect % Change
Hemoglobin	500 mg/dL	97 U/L	9
Bilirubin (conjugated)	20 mg/dL	100 U/L	8
Bilirubin (unconjugated)	25 mg/dL	107 U/L	1
Lipemia (Triglycerides)	1000 mg/dL	110 U/L	3



Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097

6/30/98  
Date

000168

## SUMMARY OF SAFETY AND EFFECTIVENESS

### Calcium Method for the Bayer ADVIA Integrated Modular System (IMS)

Listed below is a comparison of the performance between the Bayer ADVIA IMS Calcium method and a similar device that was granted clearance of substantial equivalence (Technicon CHEM 1 Calcium method). The information used in the Summary of Safety and Effectiveness was extracted from the Bayer ADVIA IMS Calcium method sheet and the CHEM 1 Calcium method sheet.

### INTENDED USE

This in vitro method is intended to quantitatively measure calcium in human serum and plasma on the Bayer ADVIA IMS. Measurements of calcium are used in the diagnosis, monitoring and treatment of a variety of diseases including parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.


METHOD		ADVIA IMS	CHEM 1
Part No.	Reagents	B41-3725-25	T01-1614-01
	Calibrators	T03-1291-62	T03-1291-62
Analytical Range		0 to 14.0 mg/dL	1 to 15 mg/dL
Precision (Total)		1.1% @ 8.4 mg/dL	2.3% @ 8.4 mg/dL
		2.2% @ 10.4 mg/dL	2.5% @ 10.6 mg/dL
		0.9% @ 13.6 mg/dL	2.2% @ 13.4 mg/dL
Correlation		y=0.96-0.8 mg/dL where y=ADVIA IMS x=CHEM 1 n=48 r=0.996 Sy.x=0.01 mg/dL	

000163

Plasma/Serum Equivalence	Plasma	Serum	Difference
	8.4 mg/dL	8.4 mg/dL	0.00
Within-run CV	0.75%	0.73%	0.02%

Interfering Substances

Bilirubin (unconjugated) 25 mg/dL	1.1%	effect change @ 9.0 mg/dL Ca
Hemoglobin 1000 mg/dL	3.0%	effect change @ 8.9 mg/dL Ca
Triglycerides 500 mg/dL	3.0%	effect change @ 9.1 mg/dL Ca



Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097



Date

000170

## SUMMARY OF SAFETY AND EFFECTIVENESS

### Glucose Method for the ADVIA IMS Systems

Listed below is a comparison of the performance of the Bayer ADVIA IMS Glucose method and a similar device that was granted clearance of substantial equivalence (Bayer Technicon Chem 1 Glucose method). The information was extracted from the Bayer ADVIA IMS Glucose method sheet.

#### INTENDED USE

The Bayer ADVIA IMS Glucose assay is an in vitro diagnostic device intended to measure glucose in human serum or plasma. Such measurements are used in the diagnosis, monitoring and treatment of carbohydrate metabolism disorders, including diabetes mellitus and neonatal hypoglycemia. This diagnostic method is not intended for use on any other diagnostic system.

GLUCOSE METHOD:	ADVIA IMS		CHEM 1	
Part Number:	Reagents B41-3732-26		T01-1460-53	
	Calibrators T03-1291-62		T03-1291-62	
Analytical Range:	0 to 800 mg/dL		0 to 675 mg/dL	
Precision (Total):	mean	% CV	mean	% CV
	(mg/dL)		(mg/dL)	
	48	3.66	87	2.7
	97	3.03	262	2.9
	293	1.80	305	2.3
			562	1.3

Regression Equation:  $y = 1.03x + 0.71$   
(serum)

where: y = ADVIA IMS  
x = Chem 1  
n = 58  
r = 0.993  
Sy.x = 11.4  
range = 51 to 534 mg/dL


Regression Equation:  $y = 0.97x + 4.12$   
(plasma qualification)

where: y = plasma  
x = serum  
n = 60  
r = 0.943  
Sy.x = 4.1  
range = 58 to 174 mg/dL


006171

*Interference*

	Interfering Substance Concentration	Glucose Concentration	Effect % Change
Hemoglobin	1000 mg/dL	297 mg/dL	0.5
Bilirubin (conjugated)	25 mg/dL	288 mg/dL	0.5
Bilirubin (unconjugated)	25 mg/dL	271 mg/dL	1.3
Lipemia (Triglycerides)	500 mg/dL	274 mg/dL	9.5



Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097



Date

000172

## SUMMARY OF SAFETY AND EFFECTIVENESS

### Ferritin Method for Bayer ADVIA™ MODULAR SYSTEM

Listed below is a comparison of the performance between the ADVIA Ferritin method and a similar device that was granted clearance of substantial equivalence (Immuno 1 Ferritin assay). The information used in the Summary of Safety and Effectiveness was extracted from the ADVIA ferritin method sheet and the Immuno 1 ferritin method sheet.

#### INTENDED USED

This *in vitro* method is intended to quantitatively measure ferritin, an iron storage protein, in human serum using Bayer Immuno 1 ferritin reagents on a Bayer ADVIA Modular System. Measurements of ferritin are used in the diagnosis and treatment of iron deficiency or iron overload disease states.

METHOD	Immuno 1 Ferritin (predicate device)		ADVIA Ferritin	
Part No.	Reagents	T01-2863-51	Reagents	B42-3902-21
	Calibrators	T03-3251-01	Calibrators	B43-3933-01
Minimum Detectable Conc.	0.3 ng/mL		0.06 ng/mL	
Precision (Total CV%)	21 ng/mL	7.1%	28 ng/mL	4.1%
	148 ng/mL	5.0%	108 ng/mL	4.8%
	344 ng/mL	5.0%	245 ng/mL	5.0%
Correlation	$y = 1.040 x - 6.132$			

where

y = Bayer ADVIA Modular System

x = Bayer Immuno 1 System

n = 50

r = 0.993

S<sub>yx</sub> = 57.50 ng/mL


000173

# **Interference**

	<b>Interfering Substance Concentration</b>	<b>Ferritin concentration</b>	<b>Ferritin (Neat concentration)</b>	<b>Effect % Change</b>
<b>Hemoglobin</b>	1000 mg/dL	179.8 ng/mL	178.3 ng/mL	0.8
<b>Bilirubin</b>	27.5 mg/dL	34.74 ng/mL	36.01ng/mL	3.5
<b>Urea Nitrogen</b>	200 mg/dL	175.1 ng/mL	182.0 ng/ml	3.8
<b>Lipemia ( Triglycerides)</b>	1110 mg/dL	212.6 ng/mL	222.6 ng/ml	4.5

  
\_\_\_\_\_

Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097

  
\_\_\_\_\_  
Date

000174



## SUMMARY OF SAFETY AND EFFECTIVENESS

### **hCG Assay for Bayer ADVIA® Integrated Modular System**

Listed below is a comparison of the performance between the ADVIA hCG method and a similar device that was granted clearance of substantial equivalence (Bayer Immuno 1® hCG Assay). The information used in the Summary of Safety and Effectiveness was extracted from the ADVIA hCG insert and the Immuno 1® hCG Assay method sheet.

#### **INTENDED USED**

This *in vitro* method is intended to quantitatively measure hCG, human chorionic gonadotropin, in human serum using ADVIA hCG Assay on a *Bayer ADVIA®* Integrated Modular System. Measurements of hCG are used in the detection of pregnancy.

METHOD	ADVIA hCG Assay		Immuno 1 hCG Assay (predicate Device)	
Part No.	Reagents	B42-3907-43	Reagents	T01-2966-51
	Calibrators	B43-3941-01	Calibrators	T03-3148-01
Minimum Detectable Conc.	0.1 mIU/mL		0.5 mIU/mL	
Precision (Total CV)	4.2% @ 12.1 mIU/mL		4.0% @ 18.3 mIU/mL	
	4.5% @ 23.9 mIU/mL		3.7% @ 55.7 mIU/mL	
	5.5% @ 198.1 mIU/mL		3.7% @ 198.1 mIU/mL	
Correlation	y = 0.99x + 1.96			
	where			
	y =	ADVIA hCG Assay		
	x =	Immuno 1 hCG Assay		
	n =	40		
	r =	1.0		
	S <sub>yx</sub> =	17.5 mIU/mL		

#### **Interfering Substances**

Interfering Substance	Interfering Substance Concentration		Analyte Concentration, mIU/mL		Effect (%)
	SI Units	(mg/dL)	Expected	Observed	
Hemoglobin	1.0 g/L	1000	17.2	16.8	-2.3
Lipids (Triglycerides)	11.3 mmol/L	1000	17.2	15.7	-8.7
Bilirubin	428 µmol/L	25	16.5	15.5	-6.1
Urea Nitrogen	71.4 mmol/L	200	17.2	15.9	-7.6

000175

*Gabriel J. Muraca, Jr.*

Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097

*6/30/98*

Date

000176

## SUMMARY OF SAFETY AND EFFECTIVENESS

### **3<sup>rd</sup> Generation TSH Assay for Bayer ADVIA<sup>®</sup> Integrated Modular System**

Listed below is a comparison of the performance between the ADVIA 3<sup>rd</sup> Generation TSH method and a similar device that was granted clearance of substantial equivalence (Bayer Immuno 1<sup>®</sup> TSH Assay). The information used in the Summary of Safety and Effectiveness was extracted from the ADVIA 3<sup>rd</sup> Generation TSH insert and the Immuno 1<sup>®</sup> TSH Assay method sheet.

#### **INTENDED USED**

This *in vitro* method is intended to quantitatively measure TSH, Thyroid Stimulating Hormone, in human serum using ADVIA 3<sup>rd</sup> Generation TSH Assay on a *Bayer ADVIA<sup>®</sup>* Integrated Modular System. Measurements of TSH are used in the diagnosis of thyroid or pituitary disorders. This assay allows the determination of TSH with 3<sup>rd</sup> generation sensitivity of less than 20% total coefficient of variation (CV) at 0.01 to 0.02  $\mu\text{IU/mL}$ , as defined by the American Thyroid Association.

#### **METHOD**

##### **ADVIA TSH Assay**

##### **Immuno 1 TSH Assay (predicate Device)**

Part No.	Reagents	B42-3921-43	Reagents	T01-2942-51
	Calibrators	B43-3948-01	Calibrators	T03-3568-01

Minimum Detectable Conc.	0.005 $\mu\text{IU/mL}$	0.03 $\mu\text{IU/mL}$
--------------------------	-------------------------	------------------------

Precision (Total CV)	13.2% @ 0.02 $\mu\text{IU/mL}$	
	2.9% @ 0.52 $\mu\text{IU/mL}$	6.3% @ 1.3 $\mu\text{IU/mL}$
	2.3% @ 4.95 $\mu\text{IU/mL}$	2.0% @ 9.0 $\mu\text{IU/mL}$
	2.6% @ 31.10 $\mu\text{IU/mL}$	1.8% @ 22.5 $\mu\text{IU/mL}$

**Correlation**  $y = 0.98x - 0.357$

where

y = ADVIA TSH Assay  
x = Immuno 1 TSH Assay  
n = 50  
r = 0.997  
 $S_{yx} = 1.48 \mu\text{IU/mL}$


000177

#### **Interfering Substances**

Interfering Substance	Interfering Substance Concentration		Analyte Concentration, $\mu\text{IU/mL}$		Effect
	SI Units	(mg/dL)	Expected	Observed	
Hemoglobin	1.0 g/L	1000	3.32	3.38	1.8
Lipids (Triglycerides)	11.3 mmol/L	1000	3.49	3.45	-0.9
Bilirubin	428 $\mu\text{mol/L}$	25	3.25	3.30	1.5
Urea Nitrogen	71.4 mmol/L	200	3.30	3.31	-1.5



Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
Bayer Corporation  
511 Benedict Avenue  
Tarrytown, New York 10591-5097



Date

000175



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JAN 29 1999

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Gabriel J. Muraca, Jr.  
Manager Regulatory Affairs  
BAYER CORPORATION  
Business Group Diagnostics  
511 Benedict Avenue  
Tarrytown, New York 10591-5097

Re: K982328

Trade Name: Bayer ADVIA® IMS™ System  
Regulatory Class: II  
Product Code: CJO, CFR, CIC, CJO, DHA, JLW, JMG  
Dated: November 12, 1998  
Received: November 19, 1998

Dear Mr. Muraca:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, flowing style.

Steven I. Gutman, M.D, M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): 15982328

Device Name: **Bayer ADVIA™ Integrated Module System (IMST™)**

Indications For Use:

**ALKALINE PHOSPHATASE  
(ALP)**

Intended Use:

The Bayer ADVIA IMS alkaline phosphatase (ALP) assay is an *in vitro* diagnostic device intended to measure ALP in human serum or plasma. Such measurements are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. This diagnostic method is not intended for use on any other diagnostic system.

**CALCIUM  
(CA)**

Intended Use:

The Bayer ADVIA IMS Calcium assay is an *in vitro* diagnostic device intended to measure calcium in human serum or plasma. Measurements of calcium are used in the diagnosis, monitoring and treatment of a variety of diseases including parathyroid disease, a variety of bone diseases, chronic renal disease, and tetany. This diagnostic method is not intended for use on any other diagnostic system.

**GLUCOSE  
(GLU)**

Intended Use:

The Bayer ADVIA IMS Glucose assay is an *in vitro* diagnostic device intended to measure glucose in human serum or plasma. Such measurements are used in the diagnosis, monitoring and treatment of carbohydrate metabolism disorders, including diabetes mellitus and neonatal hypoglycemia. This diagnostic method is not intended for use on any other diagnostic system.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

Optional Format 1-2-96)

000252

510(k) Number (if known): A982328Device Name: **Bayer ADVIA™ Integrated Module System (IMST™)**

Indications For Use:

**FERRITIN  
(FERR)**

Intended Use:

The Bayer ADVIA IMS Ferritin assay is an *in vitro* diagnostic device intended to quantitatively measure ferritin (an iron-storage protein) in human serum. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency. This diagnostic method is not intended for use on any other diagnostic system.

**HUMAN CHORIONIC GONADOTROPIN  
(hCG)**

Intended Use:

The Bayer ADVIA IMS hCG assay is an *in vitro* diagnostic device intended to quantitatively measure total beta ( $\beta$ ) in human chorionic gonadotropin (hCG) in human serum. Measurements of human chorionic gonadotropin are used in the detection of pregnancy. This diagnostic method is not intended for use on any other diagnostic system.

**THYROID STIMULATING HORMONE  
(TSH)**

Intended Use:

The Bayer ADVIA IMS TSH assay is an *in vitro* diagnostic device intended to quantitatively measure thyroid stimulating hormone (TSH) in human serum. This assay allows the determination of TSH with 3<sup>rd</sup> generation sensitivity of less than 20% total coefficient variation (CV) at 0.01 to 0.02 mIU/L or  $\mu$ IU/mL, as defined by the American Thyroid Association. Measurements thyroid stimulating hormone are used in the diagnosis of thyroid or pituitary disorders. This diagnostic method is not intended for use on any other diagnostic system.

(PLEASE DO NOT WRITE BELOW THIS LINE - ~~CONTINUE ON ANOTHER PAGE IF~~  
NEEDED)Dean Cooper  
(Division Sign-Off)  
Division of Clinical Laboratory Devices510(k) Number 1178199

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use \_\_\_\_\_  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

000253 Optional Format 1-2-96)